Vertex Prescribed drugs on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected gross sales of its medication for cystic fibrosis, and little or no contributions from a gene remedy for sickle cell illness and a not too long ago launched ache drugs.
A “tolerability concern” brought on a brief pause to an early stage research involving a carefully watched, inhaled, mRNA-based remedy for cystic fibrosis, the corporate mentioned.
Vertex shares fell 3% in after-hours buying and selling, as traders thought of a inventory buying and selling close to its all-time excessive with an extended look ahead to its subsequent leg of progress.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
